General

European Medicines Agency(EMA)

The European Union agency responsible for the scientific evaluation, supervision, and safety monitoring of medicines.

Usage Examples

EMA's CHMP adopted a positive opinion recommending approval.
The company submitted an MAA through the centralized procedure.
EMA coordinates signal assessment with national authorities.

What is EMA?

The European Medicines Agency (EMA) is the EU agency responsible for the scientific evaluation of medicines developed for use in the EU. Located in Amsterdam, EMA coordinates evaluation and supervision of medicinal products across the EU member states.

EMA manages the centralized marketing authorization procedure, which provides a single approval valid in all EU countries. EMA committees (CHMP for human medicines, PRAC for pharmacovigilance, CAT for advanced therapies) provide scientific recommendations on which the European Commission bases its decisions.

EMA also coordinates national competent authorities' activities in pharmacovigilance, inspections, and clinical trial oversight.

Regulatory Context

This term appears most often in general workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside EU REGULATION 726 2004.

FDAICHHealth Canada

When This Matters

EMA's CHMP adopted a positive opinion recommending approval.
The company submitted an MAA through the centralized procedure.
EMA coordinates signal assessment with national authorities.

Common Mistakes

Relying on generic terminology without mapping to the active jurisdiction context.
Skipping cross-links between terms, tools, and active regulatory references.
Failing to maintain a single source of truth for regulatory definitions internally.

Related Regulations

EU REGULATION 726 2004

Frequently Asked Questions

EMA evaluates medicines for the entire EU through a single application, while FDA evaluates for the US only. EMA makes recommendations to the European Commission for approval decisions; FDA makes direct approval decisions.

The centralized procedure allows companies to submit one Marketing Authorization Application to EMA and receive authorization valid in all EU member states simultaneously, rather than applying country by country.

Mandatory for: biotech products, advanced therapies, orphan medicines, HIV/AIDS/cancer/diabetes/neurodegenerative/autoimmune/viral disease treatments, and medicines with new active substances for certain conditions.